The KLOW blend is one of the more frequently searched multi-component research peptides, and the name itself is the source of most of the confusion: KLOW is not a single molecule but an acronym for a fixed combination of four separate research peptides — GHK-Cu, BPC-157, TB-500 and KPV. Each of the four is a distinct chemical entity with its own sequence, its own structural class, and its own body of published literature. This explainer breaks down what each component is at the molecular level and what published studies have actually measured for each one in research models, so the acronym stops being a black box.
What the KLOW acronym stands for
KLOW is a portmanteau built from the names of its four constituents. It is closely related to another blend, GLOW, which combines three of the four: GHK-Cu, BPC-157 and TB-500. KLOW is simply GLOW with the tripeptide KPV added — the leading “K” in the name. So the relationship is straightforward:
- GLOW = GHK-Cu + BPC-157 + TB-500 (three components)
- KLOW = KPV + GHK-Cu + BPC-157 + TB-500 (the GLOW trio plus KPV)
Because each of the four is an independent compound, understanding KLOW means understanding the four molecules individually. None of them is a derivative of another; they belong to different structural families entirely — a copper-bound tripeptide, a synthetic pentadecapeptide, a synthetic actin-binding heptapeptide, and a hormone-derived tripeptide. The combined KLOW blend is sold as a single research preparation, but chemically it is four molecules sharing a vial.
GHK-Cu: the copper tripeptide
GHK-Cu is glycyl-L-histidyl-L-lysine — a three-amino-acid peptide (glycine–histidine–lysine) bound to a copper(II) ion. The “Cu” in the name is that bound copper. GHK was first isolated from human plasma in the 1970s, and the histidine residue gives the tripeptide its characteristic high affinity for copper, forming a stable complex. It is the copper-bound form, GHK-Cu, rather than the bare peptide, that is the species studied in most of the matrix-remodeling literature.
Published research on GHK-Cu has largely centered on connective-tissue and extracellular-matrix biology in cell-culture models. In cultured fibroblasts, one study measured an increase in matrix metalloproteinase-2 (MMP-2) expression in the presence of the GHK-Cu complex, an effect the authors attributed to the copper component (Siméon et al., Life Sciences, 2000). This is the kind of measurement that defines GHK-Cu in the literature: a molecule studied for how it modulates the proteins that build and turn over the extracellular matrix in vitro — reported strictly as what the cell-culture experiment measured, not as an outcome in any organism.
BPC-157: the synthetic pentadecapeptide
BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The “BPC” stands for Body Protection Compound. The sequence corresponds to a partial fragment of a protein identified in gastric juice, which is why it is often described as a “gastric pentadecapeptide.” Unlike a hormone analog, BPC-157 is not built on a known receptor-ligand template; it is a defined synthetic sequence studied largely on its own terms.
The published BPC-157 literature is dominated by preclinical animal studies, many of them focused on tissue-repair and vascular endpoints. For example, one rat study measured the peptide’s modulatory effect on angiogenesis (new blood-vessel formation) during muscle and tendon healing models (Brcic et al., Journal of Physiology and Pharmacology, 2009). As with every compound in this blend, the relevant framing is what the model measured — a vascular and tissue-repair readout in rodents — rather than any claim about a result in a person.
TB-500: the actin-binding fragment
TB-500 is a synthetic heptapeptide (seven amino acids, sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, often written Ac-LKKTETQ). It corresponds to the central actin-binding region of a larger, naturally occurring 43-amino-acid protein called thymosin β-4 (Tβ4) — specifically residues 17–23, the segment that carries Tβ4’s actin-binding activity. TB-500 is therefore best described as a synthetic fragment of thymosin β-4, not the full protein.
The defining molecular property of thymosin β-4, and of this fragment, is G-actin sequestration: the peptide binds monomeric (globular) actin in a one-to-one ratio and holds it in an unpolymerized pool. Cell-biology research measured Tβ4 acting as a potent regulator of actin polymerization in living cells, where the amount of peptide present shifted the balance between monomeric and filamentous actin (Sanders et al., Proceedings of the National Academy of Sciences, 1992). Separate work mapped the actin-binding site on thymosin β-4 to its role in angiogenesis assays (Philp et al., The FASEB Journal, 2003). These studies describe what the molecule does to the actin cytoskeleton in experimental systems — the mechanistic basis for why the fragment is studied at all.
KPV: the C-terminal tripeptide of α-MSH
KPV is the simplest of the four: a tripeptide of lysine, proline and valine (Lys-Pro-Val). It corresponds to the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH) — the last three residues of that hormone’s sequence. Notably, KPV lacks the core sequence that α-MSH uses to bind melanocortin receptors, so it is studied as a fragment that retains certain activities of the parent hormone while being structurally distinct from the receptor-binding portion.
The published KPV literature centers on inflammatory signaling in cell and animal models. One study measured the tripeptide’s anti-inflammatory effect in murine models of inflammatory bowel disease, where it reduced markers of intestinal inflammation (Kannengiesser et al., Inflammatory Bowel Disease, 2008). Mechanistic work in this area has associated KPV with inhibition of NF-κB, a transcription-factor pathway central to inflammatory gene expression. Again, these are measurements taken in defined research models, not statements about any effect in an individual.
Frequently asked questions
What is the KLOW blend?
KLOW is a four-component research peptide blend whose name is an acronym for its constituents: KPV, GHK-Cu (sometimes the “L” is read from the “low” of GLOW), BPC-157 and TB-500. It is a single preparation containing four chemically distinct peptides, each with its own sequence and published literature.
What is the difference between KLOW and GLOW?
GLOW combines three peptides — GHK-Cu, BPC-157 and TB-500. KLOW is GLOW with the tripeptide KPV added. KLOW therefore contains four components and GLOW contains three.
Are the four KLOW components related to each other chemically?
No. They belong to different structural families: GHK-Cu is a copper-bound tripeptide, BPC-157 is a synthetic fifteen-amino-acid peptide, TB-500 is a synthetic seven-amino-acid fragment of thymosin β-4, and KPV is a three-amino-acid fragment of α-MSH. None is derived from another.
Is TB-500 the same as thymosin β-4?
No. Thymosin β-4 is a naturally occurring 43-amino-acid protein. TB-500 is a synthetic seven-amino-acid peptide corresponding to the actin-binding region (residues 17–23) of that larger protein, so it is a fragment rather than the full molecule.
What does the “Cu” in GHK-Cu mean?
The “Cu” is the chemical symbol for copper. GHK-Cu is the glycyl-histidyl-lysine tripeptide bound to a copper(II) ion, forming a copper-peptide complex. The histidine residue gives the peptide its affinity for copper.
What is KPV derived from?
KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). It is the final three amino acids of that hormone’s sequence and lacks the melanocortin-receptor-binding core of the parent molecule.
References
- Siméon A, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences. 2000. PMID: 11045606.
- Brcic L, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009. PMID: 20388964.
- Sanders MC, et al. Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proceedings of the National Academy of Sciences of the United States of America. 1992. PMID: 1584803.
- Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. The FASEB Journal. 2003. PMID: 14500546.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Disease. 2008. PMID: 18092346.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
